Zymeworks Inc. nabbed its fourth major partner by entering into a collaboration and licensing deal with GlaxoSmithKline PLC for the development of novel Fc-engineered monoclonal and bi-specific antibodies for the treatment of various undisclosed diseases.
Zymeworks Inc. nabbed its fourth major partner by entering into a collaboration and licensing deal with GlaxoSmithKline PLC for the development of novel Fc-engineered monoclonal and bi-specific antibodies for the treatment of various undisclosed diseases.
Vancouver, British Columbia, Canada-based Zymeworks may earn up to $440m in preclinical, clinical and commercial milestone fees under the agreement...
Create an account to read this article
Already a subscriber?
Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.
The drug is one of multiple candidates in the class that have been pulled from development, though it is not the company’s lead candidate.
Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.
The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.
The drugmaker reported a negative Phase III study for inclacumab, after a partial clinical hold for osivelotor and pulling Oxbryta from the market.
Just days after discontinuing a Phase III trial for a separate MASH compound, Novo Nordisk has secured the US FDA’s accelerated approval for Wegovy to treat the fatty liver disease.
The Danish firm's atopic dermatitis drug Adbry is performing well despite strong competition from Sanofi/Regeneron’s Dupixent.
